Corporate Profile and Investors’ Information

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing differentiated therapies for oncology and central nervous system disorders.

The Company is advancing a focused pipeline of high-value assets supported by strong scientific rationale, clinical validation, and clearly defined regulatory pathways.

Pipeline Overview
NDV-01 is a sustained-release intravesical co-formulation of gemcitabine and docetaxel (Gem/Doce) for the treatment of non-muscle invasive bladder cancer (NMIBC). The program has demonstrated durable responses and a favorable safety profile in an ongoing Phase 2 study. Relmada is on track to submit the NDV-01 IND by year-end 2026 and expects to initiate the Phase 3 SPECTRUM program, built on two FDA-aligned registrational pathways, upon IND clearance.

Sepranolone is a novel GABA_A modulating steroid antagonist (GAMSA) in development for compulsivity-related disorders. Relmada is on track to submit the sepranolone IND by year-end 2026 to support a Phase 2 trial in Prader-Willi syndrome.

Strategy
Relmada is focused on advancing its pipeline through disciplined clinical execution and key regulatory milestones, with an emphasis on:

• Delivering durable efficacy, favorable safety, and real-world usability
• Advancing programs with clear and efficient development pathways
• Supporting broad clinical adoption across large and well-defined patient populations

The Company also evaluates additional opportunities that align with its strategy of developing differentiated therapies with strong clinical and commercial potential.

Financial Position
As of September 30, 2026, Relmada had $202.1 million in cash, cash equivalents, and short-term investments, expected to fund operations through 2029, including completion of the two registrational cohorts of the Phase 3 SPECTRUM program.

Company Overview
Founded in 2004 and headquartered in Coral Gables, Florida, Relmada Therapeutics is committed to building a pipeline of innovative therapies designed to deliver meaningful outcomes for patients and long-term value for shareholders.